DON : Discussions on out-licensing and further cooperations

01.10.2019 | press release, Aktuell

Berlin / Teltow, 01 October 2019 - CO.DON AG is in discussions with two potential cooperation partners from Hong Kong/China regarding the out-licensing of its EU-wide approved product as well as a technical transfer of the production technology to the People's Republic of China. After a visit to the newly established production facility in Leipzig and subsequent talks in Berlin, the guests from Hong Kong confirmed their interest in working together not only to acquire the license but also to build up production capacities and to make use of CO.DON's expertise.

The talks also focussed on contract manufacturing opportunities and the establishment of further potential development projects.

Ralf M. Jakobs, Spokesman of the board of CO.DON AG: 'We are delighted about the well-founded interest of our discussion partners, with business opportunities considerably beyond the acquisition of a pure product license. For us, this means the opportunity to expand our business activities using our existing know-how in the field of production technology. Furthermore, we will offer consulting services, training and knowledge transfer by qualified CO.DON AG employees, as was already the case with the licensing for Russia. The training of qualified personnel generally takes place in the production facilities of CO.DON in Leipzig and, in addition to the actual instruction in pharmaceutical production, will also include aspects of quality control and quality assurance. We see the possible cooperation in the establishment of production facilities and in the area of contract manufacturing as further business opportunities, which we will gladly seize if the contractual possibilities are given.'

CO.DON AG develops, produces and distributes autologous cell therapies for the minimally invasive repair of cartilage defects. The product being marketed is a cell therapy product for the minimally invasive treatment of cartilage damage in the knee joint that uses only the patient's own cartilage cells ('autologous chondrocytes'). CO.DON's method is currently used in over 200 clinics in Germany and more than 14,500 patients have already been treated. In July 2017 CO.DON AG received central EU marketing authorisation for this product from the European Medicines Agency (EMA). The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Ralf M. Jakobs (Spokesman), Tilmann Bur (COO).

Further information is available from www.codon.de

Investor Relations and Press Contact:

Matthias Meißner, M.A.

Tel. [phone]

Fax [phone]

Email: [e-mail]